Cancer Research · 2005 · 103 citations · 30 references
Life SciencesMolecular BiologyOncologyCell SignalingProteomicsSignal TransductionAngiogenesisAngiogenesis In CancerCancer ProteomicsProteomic ProfilingReceptor Tyrosine Kinase SignalingTyrosine Kinase InhibitorsAurora Kinase FunctionAurora Kinase InhibitionChemical ProteomicsKinase InhibitorsKinase Target ProfilingMap KinasesMass Spectrometry ProteomicsProtein Kinase Inhibitors
Knowledge about molecular drug action is critical for the development of protein kinase inhibitors for cancer therapy. Here, we establish a chemical proteomic approach to profile the anticancer drug SU6668, which was originally designed as a selective inhibitor of receptor tyrosine kinases involved in tumor vascularization. By employing immobilized SU6668 for the affinity capture of cellular drug targets in combination with mass spectrometry, we identified previously unknown targets of SU6668 including Aurora kinases and TANK-binding kinase 1. Importantly, a cell cycle block induced by SU6668 could be attributed to inhibition of Aurora kinase activity. Moreover, SU6668 potently suppressed antiviral and inflammatory responses by interfering with TANK-binding kinase 1-mediated signal transmission. These results show the potential of chemical proteomics to provide rationales for the development of potent kinase inhibitors, which combine rather unexpected biological modes of action by simultaneously targeting defined sets of both serine/threonine and tyrosine kinases involved in cancer progression.
30
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Florian R. Greten, Lars Eckmann, Tim F. Greten et al. · Cell · 2004 · 2.4K citations · Full text
Medicine, Immunology, Oncology +16
Triggering the Interferon Antiviral Response Through an IKK-Related Pathway
Sonia Sharma, Benjamin R. tenOever, Nathalie Grandvaux et al. · Science · 2003 · 1.7K citations